Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: UHS stock price vs HCA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at HCA's multiple
Needs HCA P/E.
Implied fair value · at UHS's multiple
Needs UHS P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
UNIVERSAL HEALTH SERVICES INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
HCA Healthcare, Inc. · implied price per share
Bear
$130.81
Base
$187.37
Bull
$261.03
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
TENET HEALTHCARE CORP
UHS vs THC
COMMUNITY HEALTH SYSTEMS INC
UHS vs CYH
ACADIA PHARMACEUTICALS INC
UHS vs ACAD
Encompass Health Corp
UHS vs EHC
LABCORP HOLDINGS INC.
UHS vs LH
WEST PHARMACEUTICAL SERVICES INC
UHS vs WST
BAXTER INTERNATIONAL INC
UHS vs BAX
MCKESSON CORP
UHS vs MCK
Cigna Group
UHS vs CI
UNITEDHEALTH GROUP INC
UHS vs UNH
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe UHS deserves to trade closer to HCA's earnings multiple (i.e., market should compress the P/E gap), then buy UHS because the stock is trading at $201.26 versus a HCA-implied P/E price of $373.31 (85.5% upside) while showing stronger revenue growth (10.8%) and a high ROIC (15.2%), but monitor leverage (Net Debt/EBITDA 1.8x) and margin convergence.
UHS's current price ($201.26) is materially below HCA-implied P/E valuation (implied price $373.31, 85.5% upside). The gap is driven primarily by a much lower P/E multiple (12.0x vs HCA's 22.2x) and lower P/S (0.8x vs 1.7x), while EV/EBITDA is closer (7.5x vs 8.0x).
Supporting Metrics
